SCHEDULE: Baird Entities Report 8.5% Stake in Sanara MedTech

Baird Trust Company and its affiliates have reported a beneficial ownership of 8.5% in Sanara MedTech Inc. common stock as of December 31, 2025.

Summary

• Baird Trust Company (BTC), Baird Financial Corporation (BFC), and Baird Financial Group, Inc. (BFG) collectively reported beneficial ownership of 760,293 shares of Sanara MedTech Inc. common stock.
• This aggregate amount represents 8.5% of Sanara MedTech Inc.'s outstanding common stock.
• The percentage was calculated based on 8,901,903 shares of Common Stock outstanding as of March 18, 2025, as reported by the Issuer in its Annual Report on Form 10-K for the year ended December 31, 2024.
• The reporting persons hold shared voting power and shared dispositive power over all 760,293 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Sanara MedTech Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, indicating continued institutional interest and confidence in Sanara MedTech Inc. without suggesting any immediate operational changes or challenges.

Positives

• Increased institutional ownership by a reputable financial group like Baird can signal confidence in Sanara MedTech Inc.'s long-term prospects.
• The filing indicates a stable, passive investment, suggesting no immediate intent to influence company control, which can be viewed positively by current management.

Negatives

• The filing does not contain any negative information regarding Sanara MedTech Inc.'s operations or financial performance.

Risks

• The filing does not explicitly mention risks related to Sanara MedTech Inc.'s business operations or financial health, as it is a beneficial ownership report.

Future Outlook

The filing does not provide any forward-looking statements or guidance from Sanara MedTech Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that institutional ownership, particularly from established financial groups like Baird, can lend credibility to a company in the healthcare technology sector. While this is a passive stake, it reflects a level of institutional interest in Sanara MedTech Inc., which operates in a dynamic and competitive industry.

Comparison to Industry Standards

• This filing is a standard Schedule 13G, indicating passive beneficial ownership, which is a common practice among institutional investors like Baird Trust Company.
• The 8.5% stake is a significant, but not controlling, interest, typical for institutional portfolio holdings rather than activist positions.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Baird may be viewed positively, potentially increasing investor confidence and liquidity for Sanara MedTech Inc. common stock.

Key Dates

Recommendation

This Schedule 13G filing primarily reports a passive institutional ownership stake and does not contain new financial performance data, strategic updates, or material changes that would warrant a strong buy or sell recommendation. The reported ownership by Baird Trust Company and its affiliates is a routine disclosure of a significant, but non-controlling, position. Investors should consider this as a neutral to slightly positive indicator of institutional interest, but base investment decisions on a broader analysis of Sanara MedTech Inc.'s financial health, market position, and future prospects.

Keywords

Sanara MedTech Inc., Baird Trust Company, Baird Financial Corporation, Baird Financial Group, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Healthcare Technology